Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE)...
Concussion
AI is here. NSU forum explores how it will change business, healthcare and everything else
NATCHITOCHES, La., March 21, 2025 /PRNewswire/ -- "AI works 120 million times faster than the human brain," according to Dr....
New Psilocybin Service Center Opens to Support Athletes, Veterans, and Others with Traumatic Brain Injuries
Founded by Former NHL Player and mental health advocate Daniel Carcillo, the Portland center is the first of its kind...
PreveCeutical Announces Update to Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Header Restriction Policy in Youth Soccer Shows Promising Impact on Concussion Rates
SAN DIEGO, March 10, 2025 /PRNewswire/ -- A new study presented at the 2025 Annual Meeting of the American Academy...
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment...
Sway Medical, Inc. Announces FDA 510(k) Clearance of its Comprehensive Concussion Management System
TULSA, Okla., Feb. 26, 2025 /PRNewswire/ -- Sway Medical, Inc., the company that created the Mobile Concussion Management category, is...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Extends cash runway well into mid-2026; no new/replacement warrants issuedKENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc....
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat PlatformSARASOTA, Fla....
Firefly Neuroscience Accepted into NVIDIA Connect Program
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company"...
MYndspan and BIOS Health Partner to Make Consumer-Scale Precision Neuroscience a Reality
LONDON, Feb. 3, 2025 /PRNewswire/ - MYndspan, a pioneer in consumer brain health technology, and BIOS Health, a leader in...
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and...
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...